-+ 0.00%
-+ 0.00%
-+ 0.00%

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Barchart·12/08/2025 13:45:00
Listen to the news

64% MMR achievement by 24 weeks across all efficacy evaluable patients 

75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.